New book by Larry Connors Click here Improve your trading - See how
In the lead-in arms of the study, in which patients received a four-week lead-in of Pegintron and Rebetol followed by the addition of narlaprevir, 85-87% of patients achieved rapid virologic response (RVR), compared to 58-75% of patients in the no lead-in narlaprevir arms and no patients in the Pegintron and Rebetol control arm.
RVR, defined in this study as undetectable virus (HCV RNA) at week four of narlaprevir treatment, is recognized as an important predictor for achieving sustained virologic response. These interim results are from the Next-1 study.
Importantly, patients in the lead-in narlaprevir arms also achieved improved rates of early virologic response, defined as undetectable virus at week 12 of treatment, with 85-87% of patients having undetectable virus at week 12 of narlaprevir treatment compared to 17% of patients at week 12 in the control arm, Schering-Plough said.
The Next-1 study evaluates 12 weeks of narlaprevir 200mg or 400mg once-daily or 100mg twice daily with low-dose ritonavir (100mg) in combination with Pegintron (1.5mcg/kg once weekly) and Rebetol (600-1400mg daily), followed by Pegintron and Rebetol alone for an additional 12 or 36 weeks.
The study includes two treatment arms in which patients receive a four-week lead-in of Pegintron and Rebetol prior to receiving narlaprevir 200mg or 400mg once-daily in the above regimen. All patients in the narlaprevir arms have completed narlaprevir dosing. The control arm is Pegintron and Rebetol alone for 48 weeks.
John Vierling, lead investigator of the study, said: "These interim results, while preliminary, are very encouraging, and showed that narlaprevir has potent antiviral activity in hepatitis C. In this study, once-daily narlaprevir greatly improved viral clearance at week four of treatment in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
